SWOG clinical trial number
SWOG-8216/38

Comparison of BCG Immunotherapy and Adriamycin for Superficial Bladder Cancer

Closed
Phase
Published
Abbreviated Title
BCG - Bladder
Activated
12/01/1982
Closed
01/15/1987

Research committees

Genitourinary Cancer

Treatment

Adriamycin® BCG

Publication Information Expand/Collapse

2008

The Southwest Oncology Group: progress in cancer research [PMID18929152]

CA Coltman Seminars in Oncology 35(5):545-552

1996

Local toxicity patterns associated with intravesical bacillus calmette-guerin. A Southwest Oncology Group study.

DL Berry;BA Blumenstein;DL Magyary;DL Lamm;ED Crawford International Journal of Urology 3:98-100

1991

A randomized clinical trial of intravesical doxorubicin immunotherapy with Bacille Calmette-Guerin for transitional carcinoma of the bladder. A Southwest Oncology Group study.

DL Lamm;BA Blumenstein;ED Crawford;JE Montie;P Scardino;HB Grossman;TH Stanisic;JA Smith;J Sullivan;MF Sarosdy;JD Crissman;C Coltman, Jr NEJM 325:1205-1209

1990

Effect of colony-forming unit dose of connaught BCG on outcome to immunotherapy in superficial bladder cancer: A Southwest Oncology Group study.

B Blumenstein;D Lamm;MAS Jewett;G Humphries;L Boux;J Montie;P Scardino;H Grossman;D Crawford;JA Smith;T Stanisic Journal of Urology 143(4):340A

Fatal sepsis following intravesical bacillus calmette-guerin administrations for bladder cancer.

WH Rawls;DL Lamm;BA Lowe;ED Crawford;MF Sarosdy;JE Montie;HB Grossman;PT Scardino Urology 144:1328-1330

1989

BCG versus adriamycin intravesical therapy for in situ and papillary transitional cell carcinoma of the urinary bladder: A Southwest Oncology Group study

DL Lamm;J Crissman;ED Crawford;B Blumenstein;JE Montie;PT Scardino;HB Grossman;T Stanisic;JA Smith;M Sarosdy ASCO 8:130(504)

1986

A trial of bacillus calmette-guerin versus adriamycin in superficial bladder cancer: A South-west Oncology Group study.

K Mori;DL Lamm;ED Crawford Urology Internationalis 41(4):254-259

1985

BCG versus adriamycin in bladder cancer: A Southwest Oncology Group study.

DL Lamm;ED Crawford ASCO :#C-424

BCG versus adriamycin in the treatment of transitional cell carcinoma in-situ: A Southwest Oncology Group study.

DL Lamm;ED Crawford Proc AUA 133:184A (#283)

Intravesical adriamycin for recurrent superficial bladder cancer: A Southwest Oncology Group study.

ED Crawford;DL Lamm;JE Montie;PT Scardino;HB Grossman;T Stanisic;JA Smith;JW Sullivan Proc AUA 133:213A (#397)

BCG versus adriamycin in bladder cancer: A Southwest Oncology Group study.

DL Lamm;ED Crawford Inter-American Society for Chemotherapy, p. 49, #E7

1984

Southwest Oncology Group experience with randomized protocols for bladder cancer.

JA Smith Jr;ED Crawford In: Controlled Clinical Trials in Urologic Oncology . L Denis, GP Murphy, GR Prout Jr, F Schroder, eds. New York: Raven Press 249-254

Other Clinical Trials

SWOG Clinical Trial Number
S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"

Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200
SWOG Clinical Trial Number
CTSU/A031901